Brandon S Peplinski1, Brian A Houston2, David A Bluemke3, Steven M Kawut4, Todd M Kolb5, Richard A Kronmal6, Joao A C Lima7, David D Ralph1, Samuel G Rayner1, Zachary L Steinberg1, Ryan J Tedford2, Peter J Leary8. 1. University of Washington, Department of Medicine, Seattle, WA. 2. Medical University of South Carolina, Department of Medicine, Charleston, SC. 3. University of Wisconsin, Department of Radiology, Madison, WI. 4. Perelman School of Medicine at the University of Pennsylvania, Departments of Medicine and Epidemiology, Philadelphia, PA. 5. Johns Hopkins Hospital, Department of Medicine, Baltimore, MD. 6. University of Washington, Department of Biostatistics, Seattle, WA. 7. Johns Hopkins Hospital, Department of Medicine, Baltimore, MD; Johns Hopkins Hospital, Department of Radiology, Baltimore, MD. 8. University of Washington, Department of Medicine, Seattle, WA; University of Washington, Department of Epidemiology, Seattle, WA. Electronic address: learyp@uw.edu.
Abstract
BACKGROUND: Angiopoietin-1 and 2 (Ang1, Ang2) are important mediators of angiogenesis. Angiopoietin levels are perturbed in cardiovascular disease, but it is unclear whether angiopoietin signaling is causative, an adaptive response, or merely epiphenomenon of disease activity. METHODS AND RESULTS: In a cohort free of cardiovascular disease at baseline (Multi-Ethnic Study of Atherosclerosis [MESA]), relationships between angiopoietins, cardiac morphology, and subsequent incidence of heart failure or cardiovascular death were evaluated. In cohorts with pulmonary arterial hypertension or left heart disease, associations between angiopoietins, invasive hemodynamics, and adverse clinical outcomes were evaluated. In MESA, Ang2 was associated with a higher incidence of heart failure or cardiovascular death (hazard ratio 1.21 per standard deviation, P < .001). Ang2 was associated with increased right atrial pressure (pulmonary arterial hypertension cohort) and increased wedge pressure and right atrial pressure (left heart disease cohort). Elevated Ang2 was associated with mortality in the pulmonary arterial hypertension cohort. CONCLUSIONS: Ang2 was associated with incident heart failure or death among adults without cardiovascular disease at baseline and with disease severity in individuals with existing heart failure. Our finding that Ang2 is increased before disease onset and that elevations reflect disease severity, suggests Ang2 may contribute to heart failure pathogenesis.
BACKGROUND: Angiopoietin-1 and 2 (Ang1, Ang2) are important mediators of angiogenesis. Angiopoietin levels are perturbed in cardiovascular disease, but it is unclear whether angiopoietin signaling is causative, an adaptive response, or merely epiphenomenon of disease activity. METHODS AND RESULTS: In a cohort free of cardiovascular disease at baseline (Multi-Ethnic Study of Atherosclerosis [MESA]), relationships between angiopoietins, cardiac morphology, and subsequent incidence of heart failure or cardiovascular death were evaluated. In cohorts with pulmonary arterial hypertension or left heart disease, associations between angiopoietins, invasive hemodynamics, and adverse clinical outcomes were evaluated. In MESA, Ang2 was associated with a higher incidence of heart failure or cardiovascular death (hazard ratio 1.21 per standard deviation, P < .001). Ang2 was associated with increased right atrial pressure (pulmonary arterial hypertension cohort) and increased wedge pressure and right atrial pressure (left heart disease cohort). Elevated Ang2 was associated with mortality in the pulmonary arterial hypertension cohort. CONCLUSIONS: Ang2 was associated with incident heart failure or death among adults without cardiovascular disease at baseline and with disease severity in individuals with existing heart failure. Our finding that Ang2 is increased before disease onset and that elevations reflect disease severity, suggests Ang2 may contribute to heart failure pathogenesis.
Authors: P C Maisonpierre; C Suri; P F Jones; S Bartunkova; S J Wiegand; C Radziejewski; D Compton; J McClain; T H Aldrich; N Papadopoulos; T J Daly; S Davis; T N Sato; G D Yancopoulos Journal: Science Date: 1997-07-04 Impact factor: 47.728
Authors: Brian A Houston; Ryan J Tedford; Renee L Baxley; Brandon Sykes; Eric R Powers; Christopher D Nielsen; Daniel H Steinberg; Anbukarasi Maran; Valerian L C Fernandes; Thomas Todoran; Jeffrey A Jones; Michael R Zile Journal: Am J Cardiol Date: 2019-06-06 Impact factor: 2.778
Authors: Steven M Kawut; R Graham Barr; João A C Lima; Amy Praestgaard; W Craig Johnson; Harjit Chahal; Kofo O Ogunyankin; Michael R Bristow; Jorge R Kizer; Harikrishna Tandri; David A Bluemke Journal: Circulation Date: 2012-08-29 Impact factor: 29.690
Authors: Roberto Lorbeer; Sebastian E Baumeister; Marcus Dörr; Stephan B Felix; Matthias Nauck; Anne Grotevendt; Marcello R P Markus; Bettina von Sarnowski; Henry Völzke; Ramachandran S Vasan; Henri Wallaschofski; Wolfgang Lieb Journal: Heart Date: 2014-10-06 Impact factor: 5.994
Authors: Alexander Lukasz; Gernot Beutel; Philipp Kümpers; Agnieszka Denecke; Mechthild Westhoff-Bleck; Bernhard Schieffer; Johann Bauersachs; Jan T Kielstein; Oktay Tutarel Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: Manuel Jonas Richter; Svenja Lena Tiede; Natascha Sommer; Thomas Schmidt; Werner Seeger; Hossein Ardeschir Ghofrani; Ralph Schermuly; Henning Gall Journal: PLoS One Date: 2016-11-01 Impact factor: 3.240